Table 2.
Clinical trials of ACT for HCC the last three years (www.clinicaltrails.com).
| NCT ID | Target | Phase | Interventions | Country |
|---|---|---|---|---|
| NCT04121273 | GPC3 | 1 | CAR-T | China |
| NCT02905188 | GPC3 | 1 | CAR-T | US |
| NCT04538313 | NA | 1, 2 | TILs | China |
| NCT03884751 | GPC3 | 1 | CAR-T | China |
| NCT03899415 | HBV antigen | 1 | TCR-T | China |
| NCT03980288 | GPC3 | 1 | CAR-T | China |
| NCT03672305 | c-Met/PD-L1 | 1 | CAR-T | China |
| NCT04162158 | NA | 1, 2 | Allogeneic NK cells | China |
| NCT04368182 | AFP | 1 | TCR-T | China |
| NCT03971747 | AFP | 1 | TCR-T | China |
| NCT03993743 | CD147 | 1 | CAR-T | China |
| NCT04011033 | NA | 2, 3 | Autologous iNKT cells | China |
| NCT03941626 | DR5, EGFR vIII | 1, 2 | CAR-T/TCR-T | China |
| NCT04951141 | GPC3 | 1 | CAR-T | China |
| NCT04550663 | NKG2DL | 1 | CAR-T | China |
| NCT03441100 | MAGEA1 | 1 | TCR-T | US |
ACT, Adoptive cell therapy; GPC3, Glypican 3; CAR-T, Chimeric antigen receptor T cells; TILs, tumor-infiltrating lymphocytes; HBV, hepatitis B virus; TCR-T, T cell receptor engineered T cells; AFP, Alpha-Fetoprotein; iNKT, Invariant natural killer T; DR5, Death receptor 5; EGFR vIII, Epidermal growth factor receptor variant III; NKG2DL, NKG2D ligand; MAGEA1, MAGE family member A1.